David protein bar founder Peter Rahal targets $140M revenue in year one after acquiring key ingredient supplier

Summary

Peter Rahal, founder of RX Bar — sold to Kellogg's for roughly $240M — is nine months into his second act with David Protein, and the numbers are moving fast. The company is targeting $140M in revenue in year one, carries a $725M valuation, and has already done more, by Rahal's account, than RX Bar managed in four years.

The week's news centers on two things: that valuation and the acquisition of Epig, a key ingredient supplier. Epig was already generating 90% of its revenue from David Protein, making the vertical integration less a strategic stretch than a logical conclusion. Rahal frames it as derisking a single-source dependency while widening what the ingredient platform can eventually support across multiple brands and product lines.

The IP question

The Epig acquisition raises an obvious question about defensibility. Rahal's answer is that there is essentially one viable process to produce the molecule, and that anyone who fights through the IP litigation would spend years and significant capital to win a CPG brand rather than a pharmaceutical asset. The comparison to GLP-1s is instructive: Eli Lilly could justify that fight because a competing drug gets prescribed and reimbursed at scale. A competing protein ingredient still requires distribution, brand-building, and retail shelf space. In a category where Rahal estimates the typical IP runway is two years, he argues David Protein has roughly nine years of structural protection — enough time, at $140M and growing, to make shelf space and brand equity the real moat.

Product-led, founder-accelerated

The growth is product-led, though Rahal's track record functions as what he calls a "lubricant" — getting retailer and distributor conversations to move faster than they would for a cold-caller. The underlying product claim is that 75% of David Protein's calories come from protein, against a category average of around 50%. The protein bar market, Rahal argues, looks competitive on the surface but has low NPS and a large population of people who simply opt out because the products taste bad. Expanding the category, not just taking share within it, is the pitch.

The platform ambition

Rahal is explicit about the longer game: he'd be disappointed if David doesn't reach $1B in revenue, and he's openly thinking about a public company. The corporate structure he's designing is decentralized — David's Mars as the parent, David Protein as the operating business, Epig as a subsidiary, with future brands built from scratch rather than acquired. The analogy he uses is that brands are like human beings with their own DNA and life stages; forcing them into a single structure kills what makes them work.

He's candid that no one has figured out how to build a $100B CPG company organically. Red Bull and Monster are large but narrow. The path he sees runs through a house of brands addressing different consumer needs, with international scale as the multiplier. He estimates the addressable market for David's specific positioning — maximum protein, minimum calories — at roughly $1.5B in US revenue, which means additional brands are necessary, not optional, to justify the ambition.

The "anti-modernity" question

On the RFK and ancestral-eating backlash, Rahal's position is that nutrition science has historically not been rigorous, which created a vacuum that emotional and tribal frameworks filled. He characterizes the ancestral food movement as a post-traumatic response to decades of CFO-driven cost-cutting in food manufacturing — a reasonable reaction, but not a sophisticated one. His goal is to move the conversation toward what he sees as the actual fundamentals: caloric discipline, protein sufficiency, blood sugar management. The Epig acquisition signals that "technology" is the mechanism to get there, even if Rahal avoids using that word in consumer-facing contexts because, as he puts it, technology is not welcome in food.